Cabaletta Bio/$CABA
1D1W1MYTD1Y5YMAX
Capital at risk
About Cabaletta Bio
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
- Ticker
- $CABA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 155
- Headquarters
- Philadelphia, United States
- Website
- www.cabalettabio.com
Cabaletta Bio Metrics
BasicAdvanced
$424M
-
-$1.54
3.26
-
Price and volume
Market cap
$424M
Beta
3.26
52-week high
$4.23
52-week low
$2.00
Average daily volume
5.5M
Financial strength
Current ratio
5.789
Quick ratio
5.64
Long term debt to equity
0.03
Total debt to equity
0.122
Interest coverage (TTM)
-80.94%
Profitability
EBITDA (TTM)
-184.115
Management effectiveness
Return on assets (TTM)
-48.19%
Return on equity (TTM)
-93.20%
Valuation
Price to book
1.99
Price to tangible book (TTM)
1.99
Price to free cash flow (TTM)
-1.907
Free cash flow yield (TTM)
-52.45%
Free cash flow per share (TTM)
-1.311
Growth
Earnings per share change (TTM)
-43.35%
3-year earnings per share growth (CAGR)
-3.47%
What the Analysts think about Cabaletta Bio
Analyst ratings (Buy, Hold, Sell) for Cabaletta Bio stock.
Analyst projections of the future price of Cabaletta Bio stock.
Bulls say / Bears say
EULAR data showed more than 80% of Phase 1/2 dermatomyositis patients would have met the planned pivotal endpoint, with all five responders maintaining their response for up to 1.5 years. Many patients also stayed off immunomodulators, suggesting rese-cel could offer durable disease control rather than temporary symptom relief. (Cabaletta Bio)
Rese-cel’s reported safety profile could make treatment easier to deliver than conventional CAR-T: across 17 reported myositis patients, all had no or only mild CRS and none had ICANS. Early preconditioning-free results in pemphigus vulgaris also support a simpler regimen and could widen the addressable autoimmune market. (Cabaletta Bio, Cabaletta Bio)
Cabaletta strengthened its balance sheet with a $150 million offering and reported $225.1 million of cash, cash equivalents and short-term investments at 30 June 2026. Management expects this to fund operations into mid-2027, covering the planned myositis readout and 2027 BLA preparation. (Cabaletta Bio, Cabaletta Bio)
The pivotal evidence is still relatively small and largely uncontrolled: the planned myositis readout comes from a 17-patient cohort, while the planned systemic-sclerosis study is a roughly 25-patient single-arm trial. That leaves meaningful risk that efficacy will not hold up in larger studies or meet the FDA’s standard for approval. (Cabaletta Bio, Cabaletta Bio)
Cabaletta remains loss-making and its $150 million equity raise extends funding only into mid-2027, rather than to profitability. If trials, regulatory review or launch preparation take longer than planned, another raise could be needed and would dilute existing shareholders. (Last10K, Cabaletta Bio)
Commercial manufacturing is not yet proven at scale and depends on external partners including Lonza, ElevateBio and Cellares. Cellares supply remains conditional on continued technical progress, regulatory alignment and FDA approval, so manufacturing or quality delays could push back a potential launch even if the clinical data are positive. (Cabaletta Bio, Cabaletta Bio)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Cabaletta Bio Financial Performance
Revenues and expenses
Cabaletta Bio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Cabaletta Bio
AllUSDGBPEUR
Fund name | Fund size | $CABA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.